| Dr Mazen Rafic Fouany, MD | |
|
1001 E 2nd St, Coudersport, PA 16915-8161 | |
| (814) 274-7101 | |
| (814) 274-3251 |
| Full Name | Dr Mazen Rafic Fouany |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 1001 E 2nd St, Coudersport, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679720791 | NPI | - | NPPES |
| 102834864 0001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD445028 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| White Plains Hospital Center | White plains, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| White Plains Physician Services Pc | 3476894445 | 304 |
News Archive
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).
BioNano Genomics announced today a $10 million financing to support the ongoing development and commercialization of the IrysTM System for human genome analysis. Current investors, Battelle Ventures, Domain Associates, Gund Investment Corporation, participated in the financing.
The problem is stark: One billion people on earth don't have enough food right now. It's estimated that by 2050 there will be more than nine billion people living on the planet. Meanwhile, current agricultural practices are amongst the biggest threats to the global environment. This means that if we don't develop more sustainable practices, the planet will become even less able to feed its growing population than it is today.
ST segment-elevation myocardial infarction (STEMI) is a particularly severe type of heart attack associated with a high risk of mortality or long-term disability.
Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.
› Verified 9 days ago
| Entity Name | White Plains Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174994149 PECOS PAC ID: 4981593092 Enrollment ID: O20160506000777 |
News Archive
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).
BioNano Genomics announced today a $10 million financing to support the ongoing development and commercialization of the IrysTM System for human genome analysis. Current investors, Battelle Ventures, Domain Associates, Gund Investment Corporation, participated in the financing.
The problem is stark: One billion people on earth don't have enough food right now. It's estimated that by 2050 there will be more than nine billion people living on the planet. Meanwhile, current agricultural practices are amongst the biggest threats to the global environment. This means that if we don't develop more sustainable practices, the planet will become even less able to feed its growing population than it is today.
ST segment-elevation myocardial infarction (STEMI) is a particularly severe type of heart attack associated with a high risk of mortality or long-term disability.
Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.
› Verified 9 days ago
| Entity Name | White Plains Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1992255392 PECOS PAC ID: 4981593092 Enrollment ID: O20161219001743 |
News Archive
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).
BioNano Genomics announced today a $10 million financing to support the ongoing development and commercialization of the IrysTM System for human genome analysis. Current investors, Battelle Ventures, Domain Associates, Gund Investment Corporation, participated in the financing.
The problem is stark: One billion people on earth don't have enough food right now. It's estimated that by 2050 there will be more than nine billion people living on the planet. Meanwhile, current agricultural practices are amongst the biggest threats to the global environment. This means that if we don't develop more sustainable practices, the planet will become even less able to feed its growing population than it is today.
ST segment-elevation myocardial infarction (STEMI) is a particularly severe type of heart attack associated with a high risk of mortality or long-term disability.
Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.
› Verified 9 days ago
| Entity Name | White Plains Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124502687 PECOS PAC ID: 3476894445 Enrollment ID: O20190402000216 |
News Archive
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).
BioNano Genomics announced today a $10 million financing to support the ongoing development and commercialization of the IrysTM System for human genome analysis. Current investors, Battelle Ventures, Domain Associates, Gund Investment Corporation, participated in the financing.
The problem is stark: One billion people on earth don't have enough food right now. It's estimated that by 2050 there will be more than nine billion people living on the planet. Meanwhile, current agricultural practices are amongst the biggest threats to the global environment. This means that if we don't develop more sustainable practices, the planet will become even less able to feed its growing population than it is today.
ST segment-elevation myocardial infarction (STEMI) is a particularly severe type of heart attack associated with a high risk of mortality or long-term disability.
Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mazen Rafic Fouany, MD 1001 E 2nd St, Coudersport, PA 16915-8161 Ph: (814) 274-7101 | Dr Mazen Rafic Fouany, MD 1001 E 2nd St, Coudersport, PA 16915-8161 Ph: (814) 274-7101 |
News Archive
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).
BioNano Genomics announced today a $10 million financing to support the ongoing development and commercialization of the IrysTM System for human genome analysis. Current investors, Battelle Ventures, Domain Associates, Gund Investment Corporation, participated in the financing.
The problem is stark: One billion people on earth don't have enough food right now. It's estimated that by 2050 there will be more than nine billion people living on the planet. Meanwhile, current agricultural practices are amongst the biggest threats to the global environment. This means that if we don't develop more sustainable practices, the planet will become even less able to feed its growing population than it is today.
ST segment-elevation myocardial infarction (STEMI) is a particularly severe type of heart attack associated with a high risk of mortality or long-term disability.
Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.
› Verified 9 days ago
Dr. Celso Luiz Backes, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1001 E 2nd St, Coudersport, PA 16915 Phone: 814-274-7101 Fax: 814-274-3251 | |
Dr. James M. Clark, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1001 E 2nd St Ste N, Coudersport, PA 16915 Phone: 814-274-7101 | |
Dr. Ethan Gable, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1001 E 2nd St Ste N, Coudersport, PA 16915 Phone: 814-274-7101 |